211 related articles for article (PubMed ID: 27553064)
1. Whole body PET/CT in the follow-up of asymptomatic patients with stage IIB-IIIB cutaneous melanoma
Koskivuo I; Kemppainen J; Giordano S; Seppänen M; Veräjänkorva E; Vihinen P; Minn H
Acta Oncol; 2016 Nov; 55(11):1355-1359. PubMed ID: 27553064
[TBL] [Abstract][Full Text] [Related]
2. The role of positron emission tomography with computed tomography in the follow-up of asymptomatic cutaneous malignant melanoma patients with a high risk of disease recurrence.
Abbott RA; Acland KM; Harries M; O'Doherty M
Melanoma Res; 2011 Oct; 21(5):446-9. PubMed ID: 21849913
[TBL] [Abstract][Full Text] [Related]
3.
Jaeger ZJ; Williams GA; Chen L; Mhlanga JC; Cornelius LA; Fields RC
J Surg Oncol; 2022 Mar; 125(3):525-534. PubMed ID: 34741547
[TBL] [Abstract][Full Text] [Related]
4. PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
Madu MF; Timmerman P; Wouters MWJM; van der Hiel B; van der Hage JA; van Akkooi ACJ
Melanoma Res; 2017 Jun; 27(3):251-257. PubMed ID: 28225434
[TBL] [Abstract][Full Text] [Related]
5. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
6. Whole body positron emission tomography in follow-up of high risk melanoma.
Koskivuo IO; Seppänen MP; Suominen EA; Minn HR
Acta Oncol; 2007; 46(5):685-90. PubMed ID: 17562446
[TBL] [Abstract][Full Text] [Related]
7. S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.
Deckers EA; Wevers KP; Muller Kobold AC; Damude S; Vrielink OM; van Ginkel RJ; Been LB; van Leeuwen BL; Hoekstra HJ; Kruijff S
J Surg Oncol; 2019 Nov; 120(6):1031-1037. PubMed ID: 31468535
[TBL] [Abstract][Full Text] [Related]
8. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma.
Baker JJ; Meyers MO; Frank J; Amos KD; Stitzenberg KB; Ollila DW
Am J Surg; 2014 Apr; 207(4):549-54. PubMed ID: 24674829
[TBL] [Abstract][Full Text] [Related]
9. Clinical and Prognostic Value of
Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
[TBL] [Abstract][Full Text] [Related]
10. Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
Lewin J; Sayers L; Kee D; Walpole I; Sanelli A; Te Marvelde L; Herschtal A; Spillane J; Gyorki D; Speakman D; Estall V; Donahoe S; Pohl M; Pope K; Chua M; Sandhu S; McArthur GA; McCormack CJ; Henderson M; Hicks RJ; Shackleton M
Ann Oncol; 2018 Jul; 29(7):1569-1574. PubMed ID: 29659679
[TBL] [Abstract][Full Text] [Related]
11. The value of lymph node ultrasound and whole body
Stahlie EHA; van der Hiel B; Bruining A; van de Wiel B; Schrage YM; Wouters MWJM; van Houdt WJ; van Akkooi ACJ
Eur J Surg Oncol; 2021 May; 47(5):1157-1162. PubMed ID: 33353826
[TBL] [Abstract][Full Text] [Related]
12. Whole-body F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography imaging in the follow-up of metastatic uveal melanoma.
Klingenstein A; Haug AR; Nentwich MM; Tiling R; Schaller UC
Melanoma Res; 2010 Dec; 20(6):511-6. PubMed ID: 20890225
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of (18)F-FDG-PET/CT in early and late stages of high-risk cutaneous malignant melanoma.
Gellén E; Sántha O; Janka E; Juhász I; Péter Z; Erdei I; Lukács R; Fedinecz N; Galuska L; Remenyik É; Emri G
J Eur Acad Dermatol Venereol; 2015 Oct; 29(10):1938-44. PubMed ID: 25753249
[TBL] [Abstract][Full Text] [Related]
14. The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma.
Stahlie EHA; van der Hiel B; Stokkel MPM; Schrage YM; van Houdt WJ; Wouters MW; van Akkooi ACJ
J Surg Oncol; 2020 Dec; 122(7):1328-1336. PubMed ID: 32783266
[TBL] [Abstract][Full Text] [Related]
15. Surveillance strategies in the follow-up of melanoma patients: too much or not enough?
Kurtz J; Beasley GM; Agnese D; Kendra K; Olencki TE; Terando A; Howard JH
J Surg Res; 2017 Jun; 214():32-37. PubMed ID: 28624057
[TBL] [Abstract][Full Text] [Related]
16. Role of FDG-PET in the assessment of survival prognosis in melanoma.
Pleiss C; Risse JH; Biersack HJ; Bender H
Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
[TBL] [Abstract][Full Text] [Related]
17. False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma.
Nijhuis AAG; Dieng M; Khanna N; Lord SJ; Dalton J; Menzies AM; Turner RM; Allen J; Saw RPM; Nieweg OE; Thompson JF; Morton RL
Ann Surg Oncol; 2019 Jun; 26(6):1860-1868. PubMed ID: 30911946
[TBL] [Abstract][Full Text] [Related]
18. Routine PET-CT scans provide early and accurate recurrence detection in asymptomatic stage IIB-III melanoma patients.
Helvind NM; Aros Mardones CA; Hölmich LR; Hendel HW; Bidstrup PE; Sørensen JA; Chakera AH
Eur J Surg Oncol; 2021 Dec; 47(12):3020-3027. PubMed ID: 34120809
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
20.
Lawal I; Lengana T; Ololade K; Boshomane T; Reyneke F; Modiselle M; Vorster M; Sathekge M
Nuklearmedizin; 2017 Jun; 56(3):83-89. PubMed ID: 28154879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
